Loading news...
The program produced oil with about 45% gamma-linolenic acid after standard U.S. crushing, which the company says is among the highest levels reported at commercial scale.
GEORGE TOWN, CAYMAN ISLANDS / ACCESS Newswire / January 30, 2026 / Moolec Science S.A. ("Moolec" or the "Company"), a science-based food ingredient company focused on scalable protein solutions for the global market, today announced that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request for continued listing on The Nasdaq Stock Market, subject to certain conditions.
GEORGE TOWN, CAYMAN ISLANDS / ACCESS Newswire / January 23, 2026 / Moolec Science S.A. ("Moolec" or the "Company") today announced that Nasdaq Staff has issued a memorandum to the Nasdaq Hearings Panel (the "Panel") concluding that there is sufficient basis to grant Moolec an exception through June 29, 2026 to demonstrate compliance with the stockholders' equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) (the "Stockholders' Equity Requirement"), subject to certain disclosure conditions.
GEORGE TOWN, CAYMAN ISLANDS / ACCESS Newswire / January 22, 2026 / Moolec Science S.A. ("Moolec" or the "Company") today announced that it has received a decision from the Nasdaq Hearings Panel (the "Panel") granting the Company an exception through June 29, 2026 to demonstrate compliance with the stockholders' equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) (the "Stockholders' Equity Requirement"), subject to certain disclosure conditions.
GEORGE TOWN, CAYMAN ISLANDS / ACCESS Newswire / January 5, 2026 / Moolec Science SA ("Moolec" or the "Company") today announced that, in accordance with the resolutions passed at the extraordinary general meeting of shareholders held on December 16, 2025, and the resolutions adopted by the Company's board of directors on December 19, 2025, the Company has consummated, effective as of January 5, 2026, the previously announced share consolidation at a ratio of 15-for-1, so that all shareholders holding every 15 ordinary shares of par value of US$0.10 each will hold 1 ordinary share of par value US$1.50 each (the "Share Consolidation"). As a result, every 15 ordinary shares of the Company, par value US$0.10 per share each (with par value to be amended from time to time, the "Shares"), issued and outstanding immediately prior to the Share Consolidation, were automatically consolidated into 1 validly issued, par value US$1.50 each, fully paid and non-assessable Share, without any action required by any shareholder.
GEORGE TOWN, CAYMAN ISLANDS / ACCESS Newswire / December 31, 2025 / Moolec Science SA ("Moolec" or the "Company") received an additional determination letter (the "Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company does not currently meet the minimum stockholders' equity requirement of $2.5 million under Nasdaq Listing Rule 5550(b)(1). As previously disclosed in the Company's Form 20-F for the year ended June 30, 2025, management expects to regain compliance with the Nasdaq continued listing standards through the recognition of an estimated gain of approximately $105.8 million related to the derecognition of certain subsidiaries following their bankruptcy proceedings.
GRAND CAYMAN, CAYMAN ISLANDS / ACCESS Newswire / November 28, 2025 / On November 24, 2025, Moolec Science SA ("Moolec" or the "Company") received a letter (the "Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because it has not yet filed its Annual Report on Form 20-F for the year ended June 30, 2025 (the "Form 20-F") with the Securities and Exchange Commission (the "SEC"). As the Company stated in the form 12b-25 filed with the SEC on October 31, 2025, it was unable to file the Form 20-F in a timely manner due to complexities that arose immediately after the closing of the business combination in mid-June 2025, two weeks prior to Moolec's fiscal year end of June 30.
Moolec Science SA (NASDAQ:MLEC ) Q4 2024 Earnings Conference Call October 2, 2024 8:30 AM ET Company Participants Gaston Paladini - Chief Executive Officer Jose Lopez Lecube - Chief Financial Officer Martin Salinas - Chief Technology Officer Amit Dhingra - Chief Science Officer Bill Zima - ICR Strategic Communications Conference Call Participants Scott Fortune - Roth Capital Operator Good morning and welcome to Moolec Science's fourth quarter and full fiscal year 2024 conference call. My name is Bill Zima of ICR Strategic Communications and Advisory.
Moolec Science (NASDAQ: MLEC ) stock is taking off on Monday after the company got approval from the Food and Drug Administration (FDA) for its plant-grown animal proteins. According to a press release from the company, this covers its genetically engineered soybean that accumulates animal proteins.
Moolec Science (NASDAQ: MLEC ) stock is getting a boost on Thursday despite a lack of news from the science-based food ingredient company. There are no new press releases or filings with the Securities and Exchange Commission (SEC) that explain why the stock is rising today.
Moolec Science SA (NASDAQ:MLEC ) Q1 2024 Earnings Conference Call December 14, 2023 8:30 AM ET Company Participants Michael Bowen - ICR's, Strategic Communications and Advisory Gaston Paladini - CEO and Co-Founder Amit Dhingra - Chief Science Officer Jose Lopez Lecube - CFO Conference Call Participants Brian Wright - ROTH MKM Tom McGovern - Maxim Group Michael Bowen Good morning, and welcome to Moolec's Conference Call. My name is Michael Bowen, from ICR's, Strategic Communications and Advisory.